SV

Street Verdict

Analyst Scorecard

A record of what Rajesh Palviya said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on GlaxoSmithKline Pharmaceuticals Ltd (GLAXO), recommending buying, holding, and accumulating. The stock shows a trend reversal with higher tops and bottoms, surpassing a down-sloping trendline breakout at ₹2,550 and its prior four-week resistance zone of ₹2,585. Expected upside is ₹2,750-2,780.”

Rajesh Palviya’s track record (trackable calls only): 95 graded calls · 95% CI 46–65%

GlaxoSmithKline Pharmaceuticals LtdBullishCalled 12 Dec 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Rajesh Palviya’s full track record